argenx delivered $1.5 billion in second-quarter VYVGART product sales and entered the second half with two registrational study readouts expected before year-end.
Key Investor Takeaways – argenx (NASDAQ:ARGX) reported second-quarter product net sales of $1.52 billion, up 60% year over year and 17% sequentially. – Operating profit more than doubled to $494 million, while diluted earnings per share increased to $7.32. – The expanded VYVGART label now covers all adult generalized myasthenia gravis serotypes in the United States. – Registrational myositis and multifocal motor neuropathy results are expected in the third and fourth quarters, respectively. – Cash, cash equivalents and current financial assets rose to $5.2 billion, providing funding capacity for commercial expansion and pipeline development
Why ARGX Stock Is in Focus argenx SE (NASDAQ:ARGX) generated second-quarter product net sales of $1.52 billion, compared with $949 million in the same period of 2025. Total operating income rose to $1.54 billion from $967 million, while operating profit increased to $494 million from $201 million. Quarterly profit reached $472 million, up from $245 million, and diluted EPS climbed to $7.32 from $3.74.
For the first half of 2026, VYVGART product net sales reached $2.81 billion, compared with $1.74 billion a year earlier. Six-month operating profit increased to $887 million, while profit for the period was $838 million. Commercial momentum was supported by the US launch of VYVGART and VYVGART Hytrulo for anti-AChR antibody-negative generalized myasthenia gravis.